IngredientsDerived from dextrose (glucose), dextrin is a low-molecular-weight carbohydrate produced from the hydrolysis of starches. Dextrins are a type of water-soluble polysaccharide formed by the hydrolysis of starch. The basic chemical formula of dextrin is (C₆H₁₀O₅)ₙ, where "n" represents the number of glucose (simple sugar) molecules in the chain. The CAS registry number for dextrin is 9004-53-9.
As a class, dextrins are a family of intermediate carbohydrates situated chemically between intact starch and free sugars. Carbohydrate intermediates between starch and the sugars produced from starch by hydrolysis by dilute acids, amylase, or dry heat are referred to as dextrins; in fact, a dextrin is an oligomer of the glucose monomers of which starch is a polymer. It is an amorphous, yellow or white powder, which is (partly) soluble in water.
Within the broad dextrin family, a critical and commercially important subclass is resistant dextrin (also called indigestible dextrin or resistant maltodextrin). Resistant maltodextrin/dextrin is a glucose oligosaccharide; resistant maltodextrin and dextrin products are composed of non-digestible oligosaccharides of glucose molecules that are joined by digestible linkages and non-digestible α-1,2 and α-1,3 linkages. As of 2023, a digestion-resistant maltodextrin is considered a resistant dextrin and a resistant starch of type 5.
Dextrin can be made from any starch and is generally classified as white dextrins, yellow (or canary) dextrins, and British gums. Common source starches include corn (maize), wheat, potato, tapioca (cassava), rice, waxy maize, waxy milo, arrowroot, and sago. Maltodextrin can be derived from any starch; in the US, this starch is usually rice, corn, or potato; elsewhere, such as in Europe, it is commonly wheat.
Dextrin may be prepared by dry heating corn, waxy maize, waxy milo, potato, arrowroot, wheat, rice, tapioca, or sago starches, or by dry heating the starches after treatment with safe and suitable alkalis, acids, or pH control agents and drying the acid- or alkali-treated starch.
Dextrins also arise naturally in food preparation. The dextrinization process occurs on the surface of bread during the baking process, contributing to flavor, color, and crispness. When carbohydrate-rich foods, like breads, are dry-cooked, the starches in the food turn into dextrins, which darken as they are cooked.
Commercially, resistant dextrins are marketed under trade names such as Fibersol-2 (derived from corn starch), NUTRIOSE (available as NUTRIOSE FM06 from maize and NUTRIOSE FB06 from wheat; Roquette Frères, France), and Benefiber (wheat dextrin). NUTRIOSE 6 provides an average of 85% dietary fiber content, while NUTRIOSE 10 provides an average of 70% dietary fiber.
Resistant dextrin (RD) and resistant maltodextrin (RMD) are defined as dietary fibers by the U.S. Food and Drug Administration. Resistant dextrin has been classified as FOSHU (Foods for Special Health Uses) in Japan, or GRAS (Generally Recognized as Safe) by the Food and Drug Administration in the United States. Dextrins were evaluated previously for an acceptable daily intake (ADI) for humans by the Joint FAO/WHO Expert Committee on Food Additives in 1969 and 1974. The EU has stated that "white or yellow dextrin, roasted or dextrinated starch, starch modified by acid or alkali treatment" are not considered food additives.
Dextrin is a generic term applied to a variety of products obtained by heating a starch in the presence of small amounts of moisture and an acid. The three major reactions taking place during dextrinization are glycosidic bond cleavage (by hydrolysis), glycosidic bond formation (transglycosidation), and repolymerization.
Each dextrin type is produced by combinations of slight depolymerization (hydrolysis) and transglycosylation (molecular rearrangement); transglycosylation produces more highly branched structures and forms glycosidic linkages not found in native starches. It is these novel, non-native glycosidic bonds—particularly α-1,2 and α-1,3 linkages—that are responsible for the resistance to enzymatic digestion observed in resistant dextrins.
During dextrinization, depolymerization, transglycosylation, and repolymerization occur, leading to structural changes responsible for increasing resistance to starch enzymatic digestion.
A conventional industrial method involves the use of heat. The physicochemical process to obtain dextrin involves the use of heat (110°C–120°C) on starch moistened by diluted acid solution (1,000 parts starch, 250 parts water, 2 parts HCl). The product is subsequently dried, ground, graded, and packaged.
Enzymatic production is also practiced. A distinction is sometimes made between maltodextrins and pyrodextrins: the former are the product of dextrinization of starch using an enzyme; the latter are the product of dextrinization using heat. Newer methods such as microwave-assisted heating have been investigated to accelerate production. The conventional dextrinization time can be decreased by using microwave-assisted heating.
Resistant dextrins are characterized by their dextrose equivalent (DE) value. Dextrins are most often categorized by Dextrose Equivalence (DE) value, which is a well-known unit of measurement in the starch industry; DE is the inverse of the Degree of Polymerization (DP) and the most commonly applied quantitative measurement of starch polymer hydrolysis.
Dextrin as a deliberately produced substance has a well-documented industrial and technological history, but lacks an ethnomedical or traditional therapeutic history comparable to botanical medicines. Its discovery as a chemical entity and its early uses were industrial rather than medicinal.
The practical use of starch products, and of starch itself, developed when Egyptians, in the predynastic period, cemented strips of papyrus together with starch adhesive made from wheat. While this represents an ancient use of starch-based materials, the specific production of dextrin as a defined substance is a modern development.
An early form of starch modification practiced in the Middle Ages involved the starch being slightly hydrolyzed by vinegar. This acid hydrolysis of starch is chemically related to dextrinization, though it was not recognized as such.
The procedure for producing dextrin was first discovered in 1811 by Edme-Jean Baptiste Bouillon-Lagrange. The nineteenth century witnessed an enormous expansion of the starch industry, due largely to demands of the textile, color printing, and paper industries, and to the discovery that starch can be readily converted into a gum-like product known as dextrin.
Use in food contexts is historically limited in scope. Dextrins are used to polish cereals and processed fruits, and in the decoration of ceramics, in addition to their use in the textile and pharmaceutical industries; in the food area, dextrins enter food preparation as a thickening agent and have applications in brewing, baking, juice and cocoa drinks, distilled liquors, confectionery products, and so forth.
There is no long-standing ethnomedical or traditional medicinal use specific to wheat dextrin as a dietary therapeutic prior to its modern food-supplement use. The use of resistant dextrins as deliberate dietary fiber supplements is entirely a modern development, arising from late 20th-century food science research, particularly in Japan where Fibersol-2 was developed, and subsequently in Europe with the NUTRIOSE product line.
The bioactivity of resistant dextrin as a dietary supplement derives primarily from its structural resistance to digestion in the small intestine. The α-1,3, α-1,2 and α-1,6 glycosidic bonds cannot be decomposed by various digestive enzymes in the human body, and cannot be digested and absorbed by the small intestine after entering the human digestive tract; therefore, the dextrin with these bonds can enter the large intestine and be used by various probiotics in the large intestine as nutrients to achieve various physiological functions of dietary fibers.
Resistant dextrin is a soluble dietary fiber that is an indigestible glucose polysaccharide (rich in α-1,2 or α-1,3 linkages) formed when starch is heated and treated with enzymes, and is made of wheat or maize starch.
The principal and best-established downstream mechanism of resistant dextrin is its fermentation in the colon to produce short-chain fatty acids (SCFAs). Indigestible dextrins are composed of a glucose polymer and are considered prebiotic fiber functional ingredients; SCFAs are fermentation products of indigestible dextrin that exert important health functions, such as regulating the absorption of water and minerals and reducing colonic pH to inhibit potential pathogens and promote growth of beneficial bacteria.
In the human organism, three main SCFAs are produced by fermenting gut microbes, namely acetate, propionate, and butyrate, which constitute about 95% of SCFA content in the gastrointestinal tract.
SCFAs in turn trigger several systemic and local effects. Ingestion of resistant dextrin promoted the growth of important gastrointestinal microbiota involved in the production of SCFAs such as butyrate and propionate; this leads to the activation of GPCRs and free fatty acid receptors, which results in the elevated secretion of PYY, GLP-1, and gastric polypeptides with inhibitory properties; butyrate alone promotes the expression of peroxisome proliferator-activated receptor gamma, which improves fatty acid oxidation in the muscle tissue, leading to decreased insulin resistance.
Resistant maltodextrin (RMD), also known as indigestible dextrin, is one of the dietary fibers that has been suggested to have prebiotic functions; consumption of RMD has been found to increase the total bacterial number, particularly the genus Bifidobacterium. SCFA levels also increase upon intake of RMD.
RD has been shown to modulate the gut microbiota by increasing Bacteroides species, decreasing Clostridium perfringens, and producing several short-chain fatty acids. Microbial species modulated by resistant dextrin, including Anaerostipes, Eubacterium, and Ruminococcus species, showed higher abundances in the microbiota of participants showing more favorable clinical symptom values; these species comprise some of the major SCFA producers in the human gut.
It is reasonable to presume that RD intake may improve glucose metabolism in a manner independent of stimulating the secretion of insulin, a potential mechanism by which dietary fiber improves glucose metabolism. Additionally, via butyrate-mediated PPAR-γ activation, fatty acid oxidation in muscle tissue is enhanced, contributing to improved insulin sensitivity. Animal studies have further elucidated intracellular pathways. RD intervention had a noticeable effect on the gene transcription profile of epididymal white adipose tissue, and KEGG enrichment analysis revealed that differential genes were enriched in PI3K/AKT, AMPK, glucose-lipid metabolism, and the regulation of lipolysis in adipocyte signaling pathways.
Resistant dextrins and resistant maltodextrins are used in a wide range of functional food and beverage products because both compounds have excellent water solubility and thermal stability characteristics, provide low viscosity for a variety of food matrices, and can tolerate high temperatures and low pH levels. Resistant dextrin remains stable under conditions such as high temperature, humid environments, and a broad range of pH conditions. These properties allow it to be incorporated into foods without significantly altering taste or texture.
The effects of resistant dextrin on the gastrointestinal system are among the most studied. Evidence suggests that soluble fibers help to regulate the digestive system, may increase micronutrient absorption, stabilize blood glucose and lower serum lipids, may prevent several gastrointestinal disorders, and have an accepted role in the prevention of cardiovascular disease.
An important nuance in the literature concerns the mechanism of bowel effects. Soluble fermentable fibers such as inulin, fructooligosaccharide, and wheat dextrin do not provide a laxative effect through the same mechanism as insoluble fibers, and some fibers can be constipating (e.g., wheat dextrin and fine/smooth insoluble wheat bran particles). This is distinct from the popular assumption that all dietary fibers promote laxation; wheat dextrin's primary GI benefit appears to be in stool consistency and regularity via fermentation rather than through mechanical bulk-forming action.
A human crossover trial investigated the microbiota and gas homeostasis effects of resistant dextrin. Healthy subjects (n = 20) were given resistant dextrin (14 g/day, NUTRIOSE®) for four weeks; outcomes measured included anal evacuations of gas during daytime, digestive perception, girth, gas production in response to a standard meal, volume of colonic biomass by MRI, taxonomy and metabolic functions of fecal microbiota by shotgun sequencing, and metabolomics in urine. The adaptation of microbiota metabolism and composition after four-week dextrin consumption was associated with a shift towards fermentative pathways with reduced gas production.
Evidence strength: Moderate. Human studies confirm fermentation-related microbiota changes and SCFA production, but clinical outcomes for bowel disease states require further rigorous RCTs.
Glycemic effects represent one of the most extensively studied areas for resistant dextrin, with multiple RCTs and systematic reviews available.
An industry-sponsored program of six crossover trials conducted in five countries assessed glycemic and insulinemic responses. To evaluate the glycemic and insulinemic responses of NUTRIOSE®, six different crossover trials were conducted in five countries; 6 to 24 healthy human volunteers randomly consumed either 50 g NUTRIOSE® or 50 g anhydrous dextrose or glucose (controls), during experimental sessions of 120 to 240 minutes each. A review evaluated the results of six studies (n = 6 to 22 volunteers, with normal body mass index or overweight) with NUTRIOSE (~50 g); the glucose iAUC observed was low, ranging from 25% to 48%, and the insulin responses were from 13% to 20%, indicating that ingestion of this product causes a reduction in these responses.
A 2025 systematic review and meta-analysis of RCTs specifically in patients with type 2 diabetes (T2D) was published in BMC Nutrition. This study conducted a systematic review and meta-analysis of RCTs to evaluate the effects of RD supplementation on markers of glucose regulation in patients with T2D; the databases PubMed, Web of Science, Scopus, and the Cochrane Library were searched from inception to March 20, 2025, aiming to identify RCTs evaluating the effect of RD supplementation on fasting blood sugar, fasting insulin levels, and HbA1c in patients with T2D. This systematic review and meta-analysis demonstrated that RD supplementation may effectively lower HbA1c levels in patients with T2D; however, it is crucial to conduct more clinical studies with adequate sample sizes and rigorous methodologies to develop evidence-based treatment guidelines.
A 2026 systematic review in Nutrition Journal examined broader glycemic markers. Resistant dextrin, an indigestible glucan with various applications in the food industry, has been reported to improve insulin sensitivity and help blood glucose control. The review covered FBG, FBI, HbA1c, and HOMA-IR, searching PubMed, Embase, Web of Science, Scopus, and the Cochrane Library up to October 2024.
A human RCT in women with type 2 diabetes investigated RD as a prebiotic over eight weeks. The results demonstrated that supplementation with resistant dextrin for 8 weeks significantly decreased the levels of body weight, BMI, fasting insulin, HOMA-IR, QUICKI, IL-6, TNF-α, MDA, and endotoxin in the intervention group compared with the control group; however, reductions in the levels of FPG, HbA1c, and hs-CRP were not significant.
Evidence strength: Moderate to strong for postprandial glucose and insulin attenuation; moderate for longer-term fasting glucose and HbA1c benefits in T2D. Heterogeneity among trials and relatively small sample sizes in individual studies are acknowledged limitations.
A systematic review with meta-analysis published in the Journal of Pharmaceutical Health Care and Sciences (2017) evaluated RD for weight management. The authors conducted a systematic review with meta-analysis, searching MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, CINAHL, Web of Science, ClinicalTrials.gov, and Japana Centra Revuo Medicina; trials were included if they were RCTs comparing RD with a placebo in adults 18 years or older, reporting BMI, and including overweight or obese subjects. The review suggests that RD exerts beneficial effects on BMI and body weight in overweight adults. The studies by Li in 2010 had the lowest mean BMI at baseline (24.5 kg/m²) and the highest daily dose of RD (34 g/day) in the review.
One RCT found that RD significantly improved serum triglyceride levels and visceral fat accumulation compared to placebo over a 12-week follow-up period. A recent RCT including healthy subjects found that RD significantly improved serum triglyceride levels and visceral fat accumulation over those with a placebo in a 12-week follow-up; another RCT that included overweight subjects demonstrated that BMI was significantly lower with RD than with a placebo.
Evidence strength: Preliminary to moderate. Individual RCT results are promising, but study-level heterogeneity and limited sample sizes mean results should be interpreted cautiously. Larger, well-powered RCTs are needed.
Several short-term human studies have evaluated the effect of soluble fiber dextrin on satiety and food intake.
A double-blind preload study design tested four fiber types. The study compared the effects of four types of fiber on satiety and energy intakes at the next meal; study participants (14 men and 22 women) each took part in 6 study sessions; preloads contained soluble fiber dextrin (12 g), soluble corn fiber (11.8 g), polydextrose (11.8 g), and resistant starch (11.2 g). Relative to an isoenergetic control, only soluble fiber dextrin significantly suppressed energy intakes (p = 0.023); supplementing beverages with soluble fiber dextrin affects short-term energy intake and may have implications for weight control.
A subsequent randomized trial in 43 adults examined appetite hormones, breath hydrogen, and food intake. The study determined the effect of consuming soluble fiber dextrin (SFD) on appetite, appetitive hormones, breath hydrogen, and food intake in adults; 43 participants completed the study. For each treatment, 50% of the SFD was provided in liquid form as part of breakfast and 50% in solid form as a morning snack; appetite questionnaires, blood, and breath samples were collected immediately before breakfast and at regular intervals during the test session; the participants consumed an ad libitum lunch meal, afternoon snack, and dinner meal, with the amount eaten recorded.
However, evidence on satiety is mixed. A separate crossover study (n = 41) found different results. This crossover study investigated the effect of consuming a beverage containing SFD on appetite and food intake in adults to test the hypothesis that beverages containing 10 or 20 g of fiber from SFD would be more satiating than a control beverage; 41 participants consumed lunch with a beverage containing 0 g, 10 g, or 20 g of fiber from SFD. Results showed that consuming SFD had no effect on appetite over the 150 minutes after consumption of the lunch meal (P > 0.05).
Evidence strength: Weak to preliminary for satiety. Short-term studies show inconsistent findings. The evidence does not support a robust or consistent satiety effect at currently studied doses and meal contexts.
Human and animal evidence for prebiotic activity is substantial. Metagenomic analysis of fecal microbiota revealed the modulatory effect of resistant dextrin on several SCFA-producing bacteria; anti-inflammatory butyrate-producing species such as Eubacterium eligens may be involved in the potential dextrin-induced benefits. Similarly, resistant dextrin modulated a broad range of bacterial metabolic functions involving ribonucleotide, amino acid, and carbohydrate metabolism.
A study published in Frontiers in Microbiology (2022) addressed a Japanese cohort. Consumption of RMD was found to increase the total bacterial number, particularly the genus Bifidobacterium; additionally, SCFA levels increase upon intake of RMD.
An animal study examined anti-inflammatory effects of dextrin-type fibers in an IL-10-deficient mouse model of colitis. Male IL-10(-/-) mice were randomly assigned to 5 diets: unpurified diet with cellulose (4%; control), corn-derived hydroxypropylated new resistant starch, soluble fiber dextrin from tapioca (SFD-t) (4%), soluble fiber dextrin from corn (SFD-c) (4%), or soluble corn fiber (4%) for 12 weeks. Mice fed dextrin-based diets secreted 47–88% less colonic IL-1β, tumor necrosis factor α, and IL-23 (SFD-t diet) and IL-12 heterodimer p70, IL-6, and CXCL1 (SFD-c diet) than did the control group; SFD-t induced the growth of butyrate-producing microbes and was effective in reducing proinflammatory cytokine secretion and enterocyte injury in this mouse model of colitis. These findings are animal data and cannot be directly extrapolated to human inflammatory bowel disease without further clinical evidence.
However, not all human trials confirm compositional microbiome shifts. One study found that analyses of gut microbial community composition did not reveal associations with wheat dextrin treatment (p > 0.05, PERMANOVA using unweighted UniFrac distance at species level), noting that effects may depend on dosing schedules and habitual fiber intake. Dextrin increased propionate concentration (effect size = 0.074, p = 0.038) in at least one fecal SCFA measure.
Evidence strength: Moderate for SCFA production; moderate for increasing specific beneficial bacterial taxa such as Bifidobacterium; weak to preliminary for clinically meaningful outcomes in GI disease.
The primary mechanism proposed for lipid and cardiovascular benefits includes colonic fermentation to SCFAs (acetate, propionate, butyrate), which mediate bowel regularity, enteroendocrine signaling (GLP-1/PYY), and local anti-inflammatory effects.
Animal research suggests that resistant dextrin may reduce cholesterol absorption. Researchers have found that resistant dextrin can reduce cholesterol in mice with high cholesterol, likely because the resistant dextrin reduces the absorption efficiency of bile salts and cholesterol. These are preclinical data.
In a human RCT in women with type 2 diabetes, after 8 weeks of supplementation, significant decreases in the levels of IL-6 (28.4%), TNF-α (18.8%), MDA (25.6%), and endotoxin (17.8%) were observed in the resistant dextrin group compared with the maltodextrin group (P < 0.05). This anti-inflammatory profile is relevant to cardiovascular risk reduction, though direct cardiac endpoints were not studied.
An animal study showed that in mouse models of insulin resistance and high-fat/high-sugar feeding, RD intervention significantly enhanced glucose homeostasis and reduced lipid metabolism (TG, LDL-C; p < 0.001) and serum inflammation levels (IL-1β, IL-6; p < 0.001).
Evidence strength: Weak to preliminary in humans for direct lipid endpoints; stronger animal evidence. The 2009 Slavin et al. review concluded that soluble fibers including wheat dextrin "have an accepted role in the prevention of cardiovascular disease," but this reflects the broader soluble fiber evidence base rather than dextrin-specific cardiovascular endpoint trials.
Clinical evidence for anti-inflammatory effects exists from the T2D RCT by Aliasgharzadeh et al. (2015). Supplementation with resistant dextrin for 8 weeks significantly decreased the levels of body weight, BMI, fasting insulin, HOMA-IR, QUICKI, IL-6, TNF-α, MDA, and endotoxin in the intervention group compared with the control group. Other benefits of resistant dextrin according to clinical trials include increased GLP-2 hormone concentrations, reduced endotoxin levels, and reduced inflammation.
RD additionally demonstrates protective effects on inflammation-induced disruptions of the intestinal barrier, thought to be due to increased acetate and propionate levels, and overall enrichment of SCFA-producing bacteria.
Evidence strength: Moderate but limited by small sample sizes and the restricted populations studied (primarily women with T2D). More diverse populations and larger trials are needed.
Animal research has examined whether soluble fiber dextrin may enhance bone mineral content and calcium absorption. A 12-week rat intervention study compared eight fibers to cellulose. Two resistant starches, a soluble fiber dextrin, and polydextrose increased bone calcium content; soluble corn fiber and soluble fiber dextrin had the greatest benefit to bone properties including whole-body bone mineral content. Benefits to bone were poorly to modestly related to SCFA production, calcium absorption, or mineral retention, but some parameters were better predicted by cecal content weight, suggesting other mechanisms may be important.
The proposed mechanism is that fermentation-derived SCFA lower colonic pH, increasing the ionization and therefore solubility of calcium and other divalent minerals for absorption. However, this pathway remains to be definitively confirmed in well-designed human trials specific to resistant dextrin.
Evidence strength: Preliminary; primarily animal data. No robust human RCTs on bone mineral density outcomes have been completed specifically for dextrin supplementation.
A randomized, triple-blind, controlled clinical trial assessed resistant dextrin as a prebiotic in women with polycystic ovarian syndrome (PCOS). Gholizadeh Shamasbi et al. evaluated the effect of resistant dextrin as a prebiotic on metabolic parameters and androgen levels in women with polycystic ovarian syndrome in a randomized, triple-blind, controlled, clinical trial, published in the European Journal of Nutrition in 2019. The study examined insulin resistance markers and hormonal parameters, contributing evidence to the broader metabolic benefits of RD in hormonally complex conditions.
Evidence strength: Preliminary; based on a single RCT. Replications are needed.
Wheat dextrin is a water-soluble, low-viscosity resistant dextrin from wheat starch that functions as a fermentable dietary fiber; typical consumer dosing is 6–12 g/day.
Across clinical studies, a range of doses has been used:
Resistant dextrin is available commercially in powdered form for dissolution in beverages (e.g., Benefiber), as a supplement capsule, and as an ingredient added to functional foods and beverages. RD is often added to various food products, including beverages and baked goods, to increase fiber content without significantly altering taste or texture. The resistant dextrin has no sweet taste and can be easily dissolved in water and beverages; it can maintain the original taste of a food when used as a food additive.
The safety profile of resistant dextrin is well-established across multiple human studies and subchronic animal toxicology data. Studies reported no adverse effects of resistant dextrins up to 60 g/day on the measured outcomes. Resistant dextrins at daily doses of up to 45 to 50 g were well tolerated with no major side effects in humans, regardless of their [population characteristics].
In the four-week tolerability study at 30 and 45 g/day: No serious adverse event occurred; no diarrhea was reported, although there was a tendency for increased flatulence in a dose-dependent manner, but the increase was not substantial compared to those receiving the control (13, 14, and 17 persons reported flatulence during the last 6 days in the control, 30 g, and 45 g groups, respectively).
Ingestion of 100 g of resistant dextrin (NUTRIOSE FB 06 derived from wheat starch) was studied by Vermorel et al. (2004), and was reported not to cause severe digestive disorders. Ingestion of 100 g of resistant dextrin (NUTRIOSE FB 06 derived from wheat starch) did not cause severe digestive disorders.
Animal subchronic toxicology studies established clear no-observed-adverse-effect levels (NOAELs). The NOAELs were established by the highest tested doses: 4,360 mg/kg bw/day in males and 6,500 mg/kg bw/day in females. There was an approximately 15% increase in the absolute empty cecum weight of male and female animals treated with 5% resistant dextrin-wheat; this increase in cecum weight is considered a physiological adaptation seen after the ingestion of indigestible carbohydrates and is not considered a toxicological effect.
Wheat-derived dextrins present a specific concern for individuals with celiac disease or wheat allergy. Wheat-derived maltodextrin can contain traces of gluten, which is important for coeliacs. There have been recent reports of coeliac reactions to maltodextrin in the United States. Persons with celiac disease or non-celiac gluten sensitivity should verify the starch source of any dextrin product; corn, tapioca, and potato-derived resistant dextrins are available as alternatives.
At typical supplemental doses (up to ~45 g/day), the primary adverse effect reported is dose-dependent flatulence, related to fermentation of the substrate by colonic bacteria. This is consistent with the class-effect of fermentable dietary fibers. Diarrhea was not observed in the referenced tolerability study at 30 or 45 g/day. Larger quantities are used as a dietary supplement without adverse effects, although ingestion of very large quantities may be harmful.
No specific, well-documented pharmacokinetic drug interactions with resistant dextrin have been identified in the peer-reviewed literature reviewed here. However, consistent with all soluble dietary fibers, resistant dextrin may theoretically slow or reduce the absorption of orally administered drugs if taken simultaneously, given its capacity to affect gastric emptying rate and intestinal transit. The slowing of glucose absorption is mechanistically proposed to reduce postprandial blood glucose and insulin responses; patients with diabetes who are being pharmacologically managed should be aware of this potential additive hypoglycemic effect when initiating dextrin supplementation.
Regarding mineral interactions, the SCFA-mediated colonic acidification has been proposed to enhance calcium solubility and absorption, suggesting a potentially favorable rather than adverse interaction with minerals in some contexts. Animal data supports this finding; human confirmation is still needed.
The FDA GRAS assessment specifically notes that resistant dextrin from tapioca is GRAS for its intended use. FDA defines dietary fiber as non-digestible soluble and insoluble carbohydrates (with three or more monomeric units), and lignin that are intrinsic and intact in plants; isolated or synthetic non-digestible carbohydrates determined by FDA to have physiological effects beneficial to human health. Studies have generally excluded pregnant or lactating women; safety in these populations has not been specifically established in peer-reviewed RCTs.
Health conditions that Dextrin may help support.
Body systems that Dextrin may help support.
Go back